A-S Medication Solutions

Société pharmaceutique56 produits suivis

produits suivis

3 447 028

total des notifications

425

rappels enregistrés

65,4%

graves au total

Produits

affichage de 56 sur 56

Produit	Approuvé	Notifications ↓	Signal principal	Rappels
prednisone —	1972	491 157	Lupus érythémateux disséminé	11
levothyroxine sodium —	2000	308 680	Palpitations	100
ibuprofen capsules 200 mg —	—	195 145	Maladie rénale chronique	1
montelukast —	2012	171 338	Asthme	14
naproxen —	1987	162 981	Synovite	12
spironolactone —	1979	137 410	hyperkaliémie	11
levetiracetam —	2003	130 496	Résistance à plusieurs médicaments	18
celecoxib —	1998	129 432	Arthropathie psoriasique	4
diazepam —	1963	119 417	Abus de drogues	13
montelukast sodium —	2012	118 894	trouble des voies respiratoires obstructives	14
formoterol fumarate dihydrate —	2006	114 158	trouble des voies respiratoires obstructives	2
amoxicillin —	1974	99 955	Insuffisance rénale terminale	20
tadalafil —	2019	98 103	Hypertension artérielle pulmonaire	0
budesonide and formoterol fumarate dihydrate —	—	95 176	trouble des voies respiratoires obstructives	1
dulaglutide —	2014	86 770	Sous-dosage accidentel	3
emtricitabine —	2015	77 542	Déminéralisation osseuse	3
carbamazepine —	1986	66 038	Épilepsie	12
insulin aspart —	2000	64 485	Diminution du glucose sanguin	5
metronidazole —	1982	63 743	Infection à Clostridium difficile	15
letrozole —	1997	60 586	cancer du sein métastatique	2
fluticasone propionate and salmeterol xinafoate —	—	59 089	trouble des voies respiratoires obstructives	0
dapagliflozin —	2014	56 693	acidocétose diabétique	1
tenofovir alafenamide —	2015	41 643	Déminéralisation osseuse	0
naltrexone —	1984	39 971	Alcoolisme	17
insulin detemir —	2005	38 856	Augmentation de la glycémie	1
emtricitabine and tenofovir alafenamide —	—	35 132	Déminéralisation osseuse	0
fenofibrate —	2001	34 581	Maladie rénale chronique	11
canagliflozin —	2013	30 943	Infection du pied diabétique	1
amoxicillin and clavulanate potassium —	—	26 702	Cholestase	5
atomoxetine —	2002	26 564	blépharospasme	19
azelastine —	2000	21 326	Problème du mécanisme de délivrance du produit	9
cephalexin —	1971	21 106	Anémie néphrogénique	24
cobicistat —	2012	20 686	blessure dentaire	0
moxifloxacin —	2001	19 663	Sifflement respiratoire	38
moxifloxacin hydrochloride —	2001	19 655	Sifflement respiratoire	0
desoximetasone —	1980	18 541	Anticorps anti-peptide cyclique citrulliné positif	13
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate —	—	17 624	Diminution de la densité osseuse	0
amitriptyline hydrochloride —	1977	16 938	douleur au site de perfusion	0
trazodone hydrochloride —	1981	15 321	Tentative de suicide	0
thyroid, porcine —	—	10 359	Palpitations	0
azelastine hydrochloride —	2000	10 154	Problème du mécanisme de délivrance du produit	4
naltrexone hydrochloride —	1984	9 868	insatisfaction du patient vis-à-vis du traitement	1
beclomethasone dipropionate —	1976	9 839	Gêne nasale	7
colesevelam hydrochloride —	2000	9 134	Aucun événement indésirable	0
triazolam —	1982	8 566	Soporeux	0
etodolac —	1996	5 914	Maladie rénale chronique	2
betamethasone valerate —	1967	4 388	Flatulence vaginale	0
clindamycin hydrochloride —	1970	3 461	Éruption maculo-papuleuse	3
sodium zirconium cyclosilicate —	2018	3 424	taux de potassium sanguin anormal	0
clindamycin phosphate topical —	—	3 384	Hidradénite	5
cefuroxime axetil —	1987	3 377	Lymphœdème	0
levalbuterol hydrochloride —	1999	3 293	Asthme	0
norethindrone acetate and ethinyl estradiol and ferrous fumarate —	—	2 865	métrorragie	0
beclomethasone dipropionate hfa —	—	2 734	Problème de système d'administration du dispositif	3
insulin lispro-aabc —	2020	1 984	Irritation au site de perfusion	0
darunavir ethanolate and cobicistat —	—	1 744	Déminéralisation osseuse	0

Historique des rappels · 50 enregistrés

Date	Classe	Motif	Fabricant
28 mai 2026	II	CGMP Deviations	Ajanta Pharma USA Inc
30 avr. 2026	II	Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg Capsule.	Safecor Health, LLC
20 avr. 2026	II	Chemical contamination; presence of lead and lithium above specification	Acella Pharmaceuticals, LLC
26 févr. 2026	II	Subpotent Drug	MACLEODS PHARMA USA, INC
31 déc. 2025	II	Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.	Alvogen, Inc
18 déc. 2025	II	Presence of particulate matter - Glass like particles.	Imprimis NJOF, LLC
13 oct. 2025	II	Subpotent drug; Clavulanate Potassium component	Teva Pharmaceuticals USA, Inc
15 sept. 2025	II	Failed Dissolution Specifications.	Amerisource Health Services LLC
5 août 2025	II	Presence of foreign substance: identified as aluminum.	SUN PHARMACEUTICAL INDUSTRIES INC
29 juil. 2025	II	Subpotent drug	Pfizer
20 juin 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 juin 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 juin 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 juin 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
20 juin 2025	II	Subpotent Drug: Assay below the approved specification	ACCORD HEALTHCARE, INC.
28 mai 2025	II	Lack of Assurance of Sterility	Apotex Corp.
23 mai 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
23 mai 2025	II	Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.	Ascend Laboratories, LLC
13 mai 2025	II	Presence of Foreign Tablets/Capsules: manufacturer recalled because one tadalafil 5mg tablet was found in 500 count bottle of Celecoxib 200 mg capsules	AvKARE
9 mai 2025	II	Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsule	Alembic Pharmaceuticals Limited
10 avr. 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
10 avr. 2025	II	Subpotent	ACCORD HEALTHCARE, INC.
13 mars 2025	I	LABELING: LABEL MIX-UP: The infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.	Dr. Reddy's Laboratories, Inc.
13 mars 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
13 mars 2025	II	CGMP Deviations	Glenmark Pharmaceuticals Inc., USA
7 mars 2025	II	Super-Potent Drug: Out of specification potency results were obtained.	Mylan Institutional, Inc.
25 févr. 2025	II	Presence of Foreign Tablets/Capsules.	A-S Medication Solutions LLC
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
29 janv. 2025	II	CGMP Deviations: presence of N-Nitroso Atomoxetine Impurity above the FDA recommended limit.	Glenmark Pharmaceuticals Inc., USA
20 déc. 2024	II	Failed Impurities/Degradation Specifications: Out of specifications result observed in the drug substance for impurity test during 3-month long term stability study.	Lupin Pharmaceuticals Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
19 nov. 2024	II	Subpotent and Superpotent Drug	Mylan Institutional, Inc.
18 nov. 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc
18 nov. 2024	II	Superpotent Drug and Subpotent Drug: potency failures obtained	Viatris Inc

Classe I = probabilité raisonnable de préjudice grave · Classe II = temporaire ou réversible · Classe III = peu susceptible de causer un préjudice.

Statut d'enregistrement

Certains produits de A-S Medication Solutions ne sont pas enregistrés auprès de la FDA pour un usage humain. Pour les substances non enregistrées (peptides, SARMs sans enregistrement humain), aucun fournisseur légitime à usage humain n'existe. L'absence de filière d'approvisionnement est l'information de sécurité.